{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:28:16Z","timestamp":1786577296037,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21cm0106185"],"award-info":[{"award-number":["JP21cm0106185"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007533","name":"Kobayashi Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","award":["C2022-129"],"award-info":[{"award-number":["C2022-129"]}],"id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    SWI\/SNF-deficient cancers characterized by dual SMARCA4\/SMARCA2 loss, including subsets of lung adenocarcinoma and small cell carcinoma of the ovary, hypercalcemic type, represent a major therapeutic challenge. While SMARCA2 paralog-targeting strategies exist for single-subunit loss of SMARCA4, dual SMARCA4\/SMARCA2-deficient tumors lack actionable targets. Here, we identify the CHD3\/NuRD nucleosome remodeling complex as a critical synthetic lethal vulnerability in these malignancies. Through integrated genomic analyses, we demonstrate that in the absence of SWI\/SNF, CHD3 acts as an essential \u201cepigenetic brake\u201d specifically at the enhancer of the cell polarity regulator\n                    <jats:italic>PARD3B<\/jats:italic>\n                    . Loss of CHD3 triggers aberrant chromatin hyper-accessibility and toxic derepression of\n                    <jats:italic>PARD3B<\/jats:italic>\n                    . We further elucidate that\n                    <jats:italic>PARD3B<\/jats:italic>\n                    accumulation is a critical mediator of cell death, which is strongly associated with the attenuation of MYC signaling signatures. This attenuation likely arises from the spatial perturbation of upstream signaling hubs or secondary cellular responses, reducing MYC transcriptional output without degrading the protein itself. Therapeutically, CHD3 depletion led to robust tumor regression in dual SMARCA4\/SMARCA2-deficient xenografts, validating the in vivo mechanism of PARD3B upregulation. Collectively, our study defines a novel mode of synthetic lethality driven by \u201cgain-of-toxicity\u201d rather than the loss of survival signals, uncovering a fatal cross-complex dependency. We propose that targeting CHD3 to trigger toxic PARD3B derepression offers a promising therapeutic avenue for treatment-refractory dual SMARCA4\/SMARCA2-deficient cancers.\n                  <\/jats:p>","DOI":"10.1038\/s41698-026-01499-7","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:43:42Z","timestamp":1779446622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4\/SMARCA2-deficient cancers via derepression of PARD3B"],"prefix":"10.1038","volume":"10","author":[{"given":"Mariko","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harumi","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Ogiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"1499_CR1","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/ng.2628","volume":"45","author":"C Kadoch","year":"2013","unstructured":"Kadoch, C. et al. Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 45, 592\u2013601 (2013).","journal-title":"Nat. Genet."},{"key":"1499_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/ng.2931","volume":"46","author":"L Witkowski","year":"2014","unstructured":"Witkowski, L. et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat. Genet. 46, 438\u2013443 (2014).","journal-title":"Nat. Genet."},{"key":"1499_CR3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/ng.3399","volume":"47","author":"F Le Loarer","year":"2015","unstructured":"Le Loarer, F. et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat. Genet. 47, 1200\u20131205 (2015).","journal-title":"Nat. Genet."},{"key":"1499_CR4","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-20-1825","volume":"26","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. et al. The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer. Clin. Cancer Res. 26, 5701\u20135708 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1499_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/path.4633","volume":"238","author":"AN Karnezis","year":"2016","unstructured":"Karnezis, A. N. et al. Dual loss of the SWI\/SNF complex ATPases SMARCA4\/BRG1 and SMARCA2\/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. J. Pathol. 238, 389\u2013400 (2016).","journal-title":"J. Pathol."},{"key":"1499_CR6","doi-asserted-by":"publisher","first-page":"5508","DOI":"10.1158\/0008-5472.CAN-12-4593","volume":"73","author":"T Oike","year":"2013","unstructured":"Oike, T. et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res. 73, 5508\u20135518 (2013).","journal-title":"Cancer Res."},{"key":"1499_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/path.5705","volume":"255","author":"M Andrianteranagna","year":"2021","unstructured":"Andrianteranagna, M. et al. SMARCA4-deficient rhabdoid tumours show intermediate molecular features between SMARCB1-deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type. J. Pathol. 255, 1\u201315 (2021).","journal-title":"J. Pathol."},{"key":"1499_CR8","first-page":"372","volume":"4","author":"SB Marquez","year":"2014","unstructured":"Marquez, S. B., Thompson, K. W., Lu, L. & Reisman, D. Beyond mutations: additional mechanisms and implications of SWI\/SNF complex inactivation. Front Oncol. 4, 372 (2014).","journal-title":"Front Oncol."},{"key":"1499_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","volume":"17","author":"P Mittal","year":"2020","unstructured":"Mittal, P. & Roberts, C. W. M. The SWI\/SNF complex in cancer\u2014biology, biomarkers and therapy. Nat. Rev. Clin. Oncol. 17, 435\u2013448 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1499_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ccr.2010.09.006","volume":"18","author":"BG Wilson","year":"2010","unstructured":"Wilson, B. G. et al. Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation. Cancer Cell 18, 316\u2013328 (2010).","journal-title":"Cancer Cell"},{"key":"1499_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nm.3799","volume":"21","author":"BG Bitler","year":"2015","unstructured":"Bitler, B. G. et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med. 21, 231\u2013238 (2015).","journal-title":"Nat. Med."},{"key":"1499_CR12","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1073\/pnas.1316793111","volume":"111","author":"GR Hoffman","year":"2014","unstructured":"Hoffman, G. R. et al. Functional epigenetics approach identifies BRM\/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc. Natl. Acad. Sci. USA. 111, 3128\u20133133 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"1499_CR13","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1128\/MCB.01372-13","volume":"34","author":"BG Wilson","year":"2014","unstructured":"Wilson, B. G. et al. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol. Cell. Biol. 34, 1136\u20131144 (2014).","journal-title":"Mol. Cell. Biol."},{"key":"1499_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49063-w","volume":"15","author":"M Sasaki","year":"2024","unstructured":"Sasaki, M. et al. Targeting dependency on a paralog pair of CBP\/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers. Nat. Commun. 15, 4770 (2024).","journal-title":"Nat. Commun."},{"key":"1499_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1158\/2767-9764.CRC-24-0484","volume":"5","author":"M Sasaki","year":"2025","unstructured":"Sasaki, M., Kato, D., Yoshida, H., Shimizu, T. & Ogiwara, H. Efficacy of CBP\/p300 dual inhibitors against derepression of KREMEN2 in cBAF-dDeficient cancers. Cancer Res. Commun. 5, 24\u201338 (2025).","journal-title":"Cancer Res. Commun."},{"key":"1499_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nrm.2017.26","volume":"18","author":"CR Clapier","year":"2017","unstructured":"Clapier, C. R., Iwasa, J., Cairns, B. R. & Peterson, C. L. Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes. Nat. Rev. Mol. Cell Biol. 18, 407\u2013422 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1499_CR17","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/27699","volume":"395","author":"JK Tong","year":"1998","unstructured":"Tong, J. K., Hassig, C. A., Schnitzler, G. R., Kingston, R. E. & Schreiber, S. L. Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature 395, 917\u2013921 (1998).","journal-title":"Nature"},{"key":"1499_CR18","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1097-2765(00)80299-3","volume":"2","author":"Y Xue","year":"1998","unstructured":"Xue, Y. et al. NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol. Cell 2, 851\u2013861 (1998).","journal-title":"Mol. Cell"},{"key":"1499_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.molcel.2018.06.003","volume":"71","author":"S Bornelov","year":"2018","unstructured":"Bornelov, S. et al. The nucleosome remodeling and deacetylation complex modulates chromatin structure at sites of active transcription to fine-tune gene expression. Mol. Cell 71, 56\u201372 e54 (2018).","journal-title":"Mol. Cell"},{"key":"1499_CR20","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/febs.15754","volume":"289","author":"BJ Thompson","year":"2022","unstructured":"Thompson, B. J. Par-3 family proteins in cell polarity & adhesion. FEBS J. 289, 596\u2013613 (2022).","journal-title":"FEBS J."},{"key":"1499_CR21","doi-asserted-by":"publisher","first-page":"12249","DOI":"10.1073\/pnas.1703966114","volume":"114","author":"T Januario","year":"2017","unstructured":"Januario, T. et al. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI\/SNF mutant tumors. Proc. Natl. Acad. Sci. USA. 114, 12249\u201312254 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"1499_CR22","doi-asserted-by":"publisher","first-page":"10534","DOI":"10.1093\/nar\/gkx711","volume":"45","author":"H Hoffmeister","year":"2017","unstructured":"Hoffmeister, H. et al. CHD3 and CHD4 form distinct NuRD complexes with different yet overlapping functionality. Nucleic Acids Res. 45, 10534\u201310554 (2017).","journal-title":"Nucleic Acids Res."},{"key":"1499_CR23","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1016\/j.cell.2023.10.006","volume":"186","author":"BJE Martin","year":"2023","unstructured":"Martin, B. J. E. et al. Global identification of SWI\/SNF targets reveals compensation by EP400. Cell 186, 5290\u20135307 e5226 (2023).","journal-title":"Cell"},{"key":"1499_CR24","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1038\/sj.onc.1210611","volume":"26","author":"SA Denslow","year":"2007","unstructured":"Denslow, S. A. & Wade, P. A. The human Mi-2\/NuRD complex and gene regulation. Oncogene 26, 5433\u20135438 (2007).","journal-title":"Oncogene"},{"key":"1499_CR25","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41589-019-0329-z","volume":"15","author":"W Farnaby","year":"2019","unstructured":"Farnaby, W. et al. Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat. Chem. Biol. 15, 846 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"1499_CR26","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/nmeth.2688","volume":"10","author":"JD Buenrostro","year":"2013","unstructured":"Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10, 1213\u20131218 (2013).","journal-title":"Nat. Methods"},{"key":"1499_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"1499_CR28","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"key":"1499_CR29","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim, D., Paggi, J. M., Park, C., Bennett, C. & Salzberg, S. L. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat. Biotechnol. 37, 907\u2013915 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1499_CR30","doi-asserted-by":"publisher","first-page":"W187","DOI":"10.1093\/nar\/gku365","volume":"42","author":"F Ramirez","year":"2014","unstructured":"Ramirez, F., Dundar, F., Diehl, S., Gruning, B. A. & Manke, T. deepTools: a flexible platform for exploring deep-sequencing data. Nucleic Acids Res. 42, W187\u2013W191 (2014).","journal-title":"Nucleic Acids Res."},{"key":"1499_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326 (2011).","journal-title":"Nat. Biotechnol."},{"key":"1499_CR32","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"1499_CR33","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01499-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01499-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01499-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:04:52Z","timestamp":1786575892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01499-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1499"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01499-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8811494\/v1","asserted-by":"object"}]},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.O. received research grants from Ono Pharmaceutical Co., Ltd. during the conduct of the study. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"315"}}